FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563138187> ?p ?o ?g. }

• W2563138187 endingPage "737" @default.
• W2563138187 startingPage "731" @default.
• W2563138187 abstract "Standard care for patients with inoperable advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy. The ideal concurrent chemotherapy regimen has not been determined. The aim of this study is to retrospectively analyze the efficacy and safety of concurrent radiotherapy with carboplatin/paclitaxel administrated every three weeks (PC three-week regimen) in inoperable advanced NSCLC and compare them with the results of cisplatin/etoposide.The 43 patients with inoperable advanced NSCLC receiving concurrent chemotherapy in Peking Union Medical College Hospital from January 2012 to June 2014 were enrolled and analyzed. Of them, 15 patients received carboplatin/paclitaxel with concurrent thoracic radiotherapy; the other 28 patients received cisplatin/etoposide. Clinical characteristic, efficacy and toxicity data were compared in these two groups.For the overall population, the objective response rate (ORR) and disease control rate (DCR) were 41.9% and 90.7% respectively. The median progression free survival (PFS) was 10.6 months (95%CI: 7.4-13.8). And the median overall survival (OS) was 19.2 months (95%CI: 15.3-23.1). There were no significant differences in response rates (ORR: 33.3% vs 46.4%; DCR: 86.7% vs 92.9%, P=0.638), PFS (6.6 months vs 12.2 months, P=0.389), or OS (16.1 months vs 22.1 months, P=0.555) in either group. The adverse events were generally manageable and no treatment-related deaths occurred.Compared with PE, PC three-week regimen concurrent thoracic radiotherapy for inoperable advanced NSCLC has the similar efficacy and acceptable toxicity profile, which can be used in clinical setting.背景与目的 对于局部晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）同步放化疗是推荐的标准治疗。理想的化疗方案并未确立。本研究拟回顾性分析紫杉醇/卡铂（paclitaxel/carboplatin, PC）三周方案同步胸部放疗治疗局部晚期NSCLC的疗效和安全性，并与标准的依托泊苷/顺铂（cisplatin/etoposide, PE）方案进行比较。方法 回顾性分析北京协和医院2012年1月-2014年6月收治的局部晚期NSCLC患者共43例，其中15例接受PC三周方案同步胸部放疗，28例接受PE方案同步胸部放疗。比较两组患者的临床特征、疗效和不良反应。结果 全组患者：客观缓解率（objective response rate, ORR）为41.9%，疾病控制率（disease control rate, DCR）为90.7%，中位无疾病进展生存时间（progression-free survival, PFS）为10.6个月（95%CI: 7.4-13.8），中位总生存期（overall survival, OS）为19.2个月（95%CI: 15.3-23.1）。PC组和PE组在疗效上无统计学差异（ORR：33.3% vs 46.4%，DCR：86.7% vs 92.9%，P=0.638；PFS：6.6个月 vs 12.2个月，P=0.389；OS：16.1个月 vs 22.1个月，P=0.555）。不良反应可处理，两组均未发生治疗相关死亡。结论 PC三周方案同步胸部放疗治疗局部晚期NSCLC与标准PE方案疗效相似，不良反应可接受，在临床中可采用。." @default.
• W2563138187 created "2017-01-06" @default.
• W2563138187 creator A5018965590 @default.
• W2563138187 creator A5043365458 @default.
• W2563138187 creator A5047606095 @default.
• W2563138187 creator A5053533157 @default.
• W2563138187 creator A5064825310 @default.
• W2563138187 creator A5064887006 @default.
• W2563138187 creator A5065380119 @default.
• W2563138187 creator A5066716873 @default.
• W2563138187 creator A5090482004 @default.
• W2563138187 creator A5090691776 @default.
• W2563138187 date "2016-11-20" @default.
• W2563138187 modified "2023-10-16" @default.
• W2563138187 title "[Outcomes and Toxicity of Concurrent Radiotherapy with Carboplatin/Paclitaxel 
Administrated Every Three Weeks in Inoperable Advanced 
Non-small Cell Lung Cancer: 
A Retrospective Study from A Single Center]." @default.
• W2563138187 cites W1944220675 @default.
• W2563138187 cites W1968899146 @default.
• W2563138187 cites W1971564125 @default.
• W2563138187 cites W1995805135 @default.
• W2563138187 cites W2027622870 @default.
• W2563138187 cites W2062581935 @default.
• W2563138187 cites W2068551729 @default.
• W2563138187 cites W2075141037 @default.
• W2563138187 cites W2086560827 @default.
• W2563138187 cites W2096103793 @default.
• W2563138187 cites W2102361674 @default.
• W2563138187 cites W2104701073 @default.
• W2563138187 cites W2105024669 @default.
• W2563138187 cites W2121138562 @default.
• W2563138187 cites W2124621771 @default.
• W2563138187 cites W2134417792 @default.
• W2563138187 cites W2135631135 @default.
• W2563138187 cites W2136240226 @default.
• W2563138187 cites W2140469315 @default.
• W2563138187 cites W2152939220 @default.
• W2563138187 cites W2153865661 @default.
• W2563138187 cites W2155053061 @default.
• W2563138187 cites W2160797118 @default.
• W2563138187 cites W2161523978 @default.
• W2563138187 cites W2171835824 @default.
• W2563138187 cites W2263280562 @default.
• W2563138187 cites W2275338432 @default.
• W2563138187 cites W2340593423 @default.
• W2563138187 doi "https://doi.org/10.3779/j.issn.1009-3419.2016.11.03" @default.
• W2563138187 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5999639" @default.
• W2563138187 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27866515" @default.
• W2563138187 hasPublicationYear "2016" @default.
• W2563138187 type Work @default.
• W2563138187 sameAs 2563138187 @default.
• W2563138187 citedByCount "2" @default.
• W2563138187 countsByYear W25631381872019 @default.
• W2563138187 countsByYear W25631381872020 @default.
• W2563138187 crossrefType "journal-article" @default.
• W2563138187 hasAuthorship W2563138187A5018965590 @default.
• W2563138187 hasAuthorship W2563138187A5043365458 @default.
• W2563138187 hasAuthorship W2563138187A5047606095 @default.
• W2563138187 hasAuthorship W2563138187A5053533157 @default.
• W2563138187 hasAuthorship W2563138187A5064825310 @default.
• W2563138187 hasAuthorship W2563138187A5064887006 @default.
• W2563138187 hasAuthorship W2563138187A5065380119 @default.
• W2563138187 hasAuthorship W2563138187A5066716873 @default.
• W2563138187 hasAuthorship W2563138187A5090482004 @default.
• W2563138187 hasAuthorship W2563138187A5090691776 @default.
• W2563138187 hasConcept C126322002 @default.
• W2563138187 hasConcept C141071460 @default.
• W2563138187 hasConcept C143998085 @default.
• W2563138187 hasConcept C2776256026 @default.
• W2563138187 hasConcept C2776694085 @default.
• W2563138187 hasConcept C2778119113 @default.
• W2563138187 hasConcept C2778239845 @default.
• W2563138187 hasConcept C2778424827 @default.
• W2563138187 hasConcept C2781413609 @default.
• W2563138187 hasConcept C2781451048 @default.
• W2563138187 hasConcept C509974204 @default.
• W2563138187 hasConcept C71924100 @default.
• W2563138187 hasConceptScore W2563138187C126322002 @default.
• W2563138187 hasConceptScore W2563138187C141071460 @default.
• W2563138187 hasConceptScore W2563138187C143998085 @default.
• W2563138187 hasConceptScore W2563138187C2776256026 @default.
• W2563138187 hasConceptScore W2563138187C2776694085 @default.
• W2563138187 hasConceptScore W2563138187C2778119113 @default.
• W2563138187 hasConceptScore W2563138187C2778239845 @default.
• W2563138187 hasConceptScore W2563138187C2778424827 @default.
• W2563138187 hasConceptScore W2563138187C2781413609 @default.
• W2563138187 hasConceptScore W2563138187C2781451048 @default.
• W2563138187 hasConceptScore W2563138187C509974204 @default.
• W2563138187 hasConceptScore W2563138187C71924100 @default.
• W2563138187 hasIssue "11" @default.
• W2563138187 hasLocation W25631381871 @default.
• W2563138187 hasOpenAccess W2563138187 @default.
• W2563138187 hasPrimaryLocation W25631381871 @default.
• W2563138187 hasRelatedWork W151172257 @default.
• W2563138187 hasRelatedWork W1847381023 @default.
• W2563138187 hasRelatedWork W1989051367 @default.
• W2563138187 hasRelatedWork W1993400037 @default.
• W2563138187 hasRelatedWork W2022084568 @default.
• W2563138187 hasRelatedWork W2277416945 @default.
• W2563138187 hasRelatedWork W2348495938 @default.

• next